Board member Mick Hitchcock named interim CEO replacing Thomas Butler.COO and President Ramses Erdtmann continuing at Biomea in current role.REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- ...
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...
Board member Mick Hitchcock named interim CEO replacing Thomas Butler.COO and President Ramses Erdtmann continuing at Biomea in current role.REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- ...
We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...
Digital therapeutics coupled with drugs has the potential to transform health care and change the way patients are treated, ...
Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.
First granted in 2020, the waiver allows members of DISA Entertainment Compliance Solutions to conduct limited queries of the ...
2d
DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback